Steve Pakola, Chief Medical Officer of REGENXBIO Inc., filed a Form 4 on November 3, 2026, disclosing the acquisition of 34,722 shares of common stock underlying a restricted stock unit award dated November 1, 2026.

Key Highlights

  • Reporting person: Steve Pakola, Chief Medical Officer of REGENXBIO Inc. (NASDAQ:RGNX)
  • Transaction: Acquisition of 34,722 shares of common stock underlying a time-based restricted stock unit (RSU) award, coded "A" (acquired)
  • Price paid: $0.00 per share at grant
  • Vesting schedule: 1/3 of shares vest on each of November 1, 2027, November 1, 2028, and November 1, 2029, subject to continuous service to the issuer
  • Beneficial ownership following transaction: 240,263 shares of common stock held directly
  • Transaction date: November 1, 2026

Pakola RSU Grant Details and Ownership Position at REGENXBIO

According to the Form 4 filed with the SEC on November 3, 2026, Steve Pakola, serving as Chief Medical Officer of REGENXBIO Inc. (NASDAQ:RGNX), received a time-based restricted stock unit award on November 1, 2026. The award covers 34,722 shares of REGENXBIO common stock and was acquired at a price of $0.00, consistent with a grant rather than an open-market purchase.

The filing states that "1/3rd of the shares subject to the RSU award shall vest on each of November 1, 2027, November 1, 2028, and November 1, 2029, while the recipient provides continuous service to the Issuer." Following this transaction, Pakola's directly held beneficial ownership of REGENXBIO common stock stands at 240,263 shares, according to the filing. The form was signed by Patrick J. Christmas as attorney-in-fact on November 3, 2026.

The filing indicates no derivative securities were acquired or disposed of in connection with this transaction. The RSU award appears in Table I of the Form 4 as a non-derivative security acquisition, with transaction code "A" indicating an acquisition rather than a disposition.

What Was Disclosed

REGENXBIO's Chief Medical Officer, Steve Pakola, disclosed receipt of a 34,722-share RSU award on November 1, 2026, vesting in equal thirds over three years beginning November 1, 2027, bringing his total direct beneficial ownership to 240,263 shares.